48
Participants
Start Date
April 13, 2021
Primary Completion Date
January 31, 2024
Study Completion Date
May 31, 2024
APG-2575
APG-2575 orally once daily, every 28 days as a cycle.
Rd
Lenalidomide administered at a dose of 25 mg orally (PO) on Days 1 through 21 of each 28-day cycle, dexamethasone administered at a dose of 40 mg (or 20 mg for patients\>75 years old) on Days 1, 8, 15, and 22 of a repeated 28-day cycle.
NOT_YET_RECRUITING
Beijing Chao-yang Hospital of Capital Medical University, Beijing
NOT_YET_RECRUITING
People's hospital of Jiangsu Province, Nanjing
RECRUITING
The First Affiliated Hospital of Soochow University, Suzhou
NOT_YET_RECRUITING
Union Hospital Tongji Medical College of Huazhong University of Science ang Technology, Wuhan
NOT_YET_RECRUITING
The First Affilated Hospital of Zhejiang University School of Medicine, Hangzhou
NOT_YET_RECRUITING
The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou
NOT_YET_RECRUITING
Zhongnan Hospital of Wuhan University, Wuhan
NOT_YET_RECRUITING
Henan Cancer Hospital, Zhengzhou
NOT_YET_RECRUITING
Sun Yat-sen University Cancer Center, Guangzhou
NOT_YET_RECRUITING
Guangdong Province People's Hospital, Guangzhou
NOT_YET_RECRUITING
The First Affiliated Hospital of Sun Yat-sen University, Guangzhou
NOT_YET_RECRUITING
Shenzhen Second People's Hospital, Shenzhen
Lead Sponsor
Ascentage Pharma Group Inc.
INDUSTRY